Guglielmo Marconi

Marconi in 1908 Guglielmo Giovanni Maria Marconi, 1st Marquess of Marconi (; ; 25 April 1874 – 20 July 1937) was an Italian electrical engineer, inventor, physicist and politician known for his creation of a practical radio wave-based wireless telegraph system. This led to Marconi being credited as the inventor of radio and sharing the 1909 Nobel Prize in Physics with Karl Ferdinand Braun "in recognition of their contributions to the development of wireless telegraphy". His work laid the foundation for the development of radio, television and all modern wireless communication systems.

Marconi was also an entrepreneur and businessman who founded the Wireless Telegraph & Signal Company (which became the Marconi Company) in the United Kingdom in 1897. In 1929, Marconi was ennobled as a marquess (''marchese'') by Victor Emmanuel III. In 1931, he set up Vatican Radio for Pope Pius XI.

Provided by Wikipedia
Showing 1 - 5 results of 5 for search 'G. Marconi', query time: 0.03s Refine Results
  1. 1
    Developing Growth‐Associated Molecular Markers Via High‐Throughput Phenotyping in Spinach

    Developing Growth‐Associated Molecular Markers Via High‐Throughput Phenotyping in Spinach by Henry O. Awika, Renesh Bedre, Junho Yeom, Thiago G. Marconi, Juan Enciso, Kranthi K. Mandadi, Jinha Jung, Carlos A. Avila

    Published 2019-11-01
    Get full text
    Article
  2. 2
    P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN

    P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN by C. Sartor, I. Vigliotta, V. Robustelli, G. Cristiano, J. Nanni, L. Zannoni, S. Parisi, S. Paolini, G. Marconi, G. Martinelli, A. Curti, M. Cavo, C. Terragna, C. Papayannidis

    Published 2022-06-01
    Get full text
    Article
  3. 3
    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT... by A. DeZern, G. Marconi, D. Deeren, M. Diez Campelo, M. Lübbert, P. Krishnamurthy, Z. Nagy, G. Basak, A. Jonášová, E. Morozova, K. Geissler, Y. Ofran, H. Kelley, A. Volkert, K. Baker, Q. Kang-Fortner, G. Hodgson, C. Madigan, D. A. Roth, M. Kelly, P. Fenaux

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.

    P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. by G. Martinelli, A. Santoro, C. Gambacorti-Passerini, S. Vives Polo, S. R. Solomon, S. Mukherjee, E. Lech-Maranda, M. Yair Levy, A. Wierzbowska, M. Calbacho-Robles, G. Marconi, M. Benedetta Giannini, I. Cano, L. Torres Miñana, E. Acuña-Cruz, N. Angelosanto, A. Galleu, S. Baldini, S. Blotta, F. Ravandi, P. Montesinos

    Published 2022-06-01
    Get full text
    Article
  5. 5
    PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN

    PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN by N. Pemmaraju, G. Martinelli, E. Todisco, C. Tarella, P. Montesinos, A. A. Lane, H. P. Erba, K. L. Sweet, R. B. Walter, E. Deconinck, E. S. Wang, A. Aribi, M. L. Ulrikson, M. Y. Levy, D. Lebon, G. Marconi, D. J. DeAngelo, D. Rizzieri, M. Konopleva, C. M. Sloss, J. Wang, K. A. Malcolm, P. A. Zweidler-McKay, N. G. Daver

    Published 2022-06-01
    Get full text
    Article

Search Tools: